Abstract
TCR gamma/delta profiles were analyzed in 13 multiple myeloma patients after allogeneic non-myeloablative transplantation. Results show that both aGVHD and minimal residual disease (MRD) eradication did significantly affect TCR gamma/delta profile. During follow-up, six patients developed an aGVHD episode; in five of them, this event fitted with a modification of the TCR profile. Eleven patients achieved PCR-negativity during follow-up. In the 90% of them, the appearance of a new predominant TCR peak was concomitant to the disappearance of the IgH clone. These results suggest that different T gamma/delta populations would sustain GVM and GVH effects after non-myeloablative allogeneic transplant.
MeSH terms
-
Adult
-
Aged
-
Clone Cells
-
Female
-
Follow-Up Studies
-
Graft vs Host Disease / genetics*
-
Graft vs Host Disease / immunology
-
Graft vs Host Disease / therapy
-
Graft vs Tumor Effect / genetics*
-
Graft vs Tumor Effect / immunology
-
Humans
-
Immunoglobulin Heavy Chains / genetics
-
Male
-
Middle Aged
-
Multiple Myeloma / genetics*
-
Multiple Myeloma / immunology
-
Multiple Myeloma / therapy*
-
Neoplasm, Residual / genetics*
-
Neoplasm, Residual / immunology
-
Neoplasm, Residual / therapy
-
Peripheral Blood Stem Cell Transplantation / adverse effects*
-
Peripheral Blood Stem Cell Transplantation / methods
-
Receptors, Antigen, T-Cell, gamma-delta / analysis
-
Receptors, Antigen, T-Cell, gamma-delta / genetics*
-
Transplantation, Homologous
-
Treatment Outcome
Substances
-
Immunoglobulin Heavy Chains
-
Receptors, Antigen, T-Cell, gamma-delta